Abstract
CYC-202, the lead compound from the CYC-200 series of small-molecule cyclin-dependent kinase inhibitors, is under development by Cyclacel for the potential treatment of various cancers and inflammatory diseases, including glomerulonephritis. The compound is currently undergoing phase II clinical trials in non-small-cell lung cancer and breast tumor.
MeSH terms
-
Animals
-
Antineoplastic Agents / chemistry
-
Antineoplastic Agents / pharmacology
-
Antineoplastic Agents / therapeutic use*
-
Clinical Trials as Topic
-
Drugs, Investigational / chemistry
-
Drugs, Investigational / pharmacology
-
Drugs, Investigational / therapeutic use*
-
Humans
-
Purines / chemistry
-
Purines / pharmacology
-
Purines / therapeutic use*
-
Roscovitine
Substances
-
Antineoplastic Agents
-
Drugs, Investigational
-
Purines
-
Roscovitine